¹⁷⁷Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer

Table 2

Description of the reported disease of patients and the radiotracer used in each case for evaluation of the response to ¹⁷⁷Lu-iPSMA therapy.

Patient no.	Age	Reported disease	Radiotracer
1	86	Prostate cancer, resistant to castration, with retroperitoneal, external, and common iliac bilateral chains lymph node metastases	^68Ga-iPSMA
2	72	Prostate cancer, resistant to castration, with bone, lungs, liver, and lymph node metastases; right nephrectomy and adrenalectomy with resection of the diaphragm by tumor infiltration	[^99mTc]Tc-iPSMA
3	71	Prostate cancer, resistant to castration, with bone and lymph node metastases	[^99mTc]Tc-iPSMA
4	61	Prostate cancer with lymph node metastasis	[^99mTc]Tc-iPSMA
5	60	Prostate cancer, resistant to castration, diabetes mellitus type 2, chronic kidney disease, kidney transplant, with liver, retroperitoneal, and left iliac chain lymph nodes and vertebral T6 metastases	[^99mTc]Tc-iPSMA
6	72	Prostate cancer, resistant to castration, with inguinal lymph nodes and bone metastases; kidney cancer with left nephrectomy; gastric cancer	^68Ga-PSMA-11
7	58	Prostate cancer, resistant to castration, with right sacrum bone metastasis; retroperitoneal, iliac bilateral chains, inguinal, and gluteus lymph node metastases, bladder and liver metastases (Ra-223 treatment)	^68Ga-PSMA-11
8	65	Prostate cancer with liver and lymph node metastases	^68Ga-PSMA-11
9	66	Prostate cancer, resistant to castration, with multiple bone metastases (radiotherapy treatment)	^68Ga-PSMA-11
10	74	Prostate cancer, resistant to castration, with multiple lymph node metastases (brachytherapy treatment)	^68Ga-iPSMA